Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sanofi-Aventis S.A. ADR (NQ: SNY )

48.57 -0.25 (-0.51%)
Streaming Delayed Price Updated: 3:36 PM EDT, May 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sanofi-Aventis S.A. ADR

< Previous 1 2
...
19 20 21 22 23 24 25 26 Next >
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc... 
Via Benzinga
Denali Highlights Encouraging Early Data, Update For Amyotrophic Lateral Sclerosis Program
Denali Therapeutics Inc (NASDAQ: DNLI) announced data from the Phase 1 trial evaluating DNL343, eIF2B activator, in 95 healthy volunteers. DNL343 was generally... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For October PDUFA Dates
Following a mixed month for regulatory approvals, biotech investors now turn toward a month of plenty as far as Food and Drug Administration decisions are concerned. Four new... 
Via Benzinga
Multiple Bits Of Bad News
Republican debt ceiling brinkmanship boosted yields way over what stocks can pay, with info-tech the big loser. 
Via Talk Markets
Sanofi Stops Work On Its mRNA COVID-19 Vaccine: What You Need To Know
Sanofi SA (NASDAQ: SNY) is dropping plans for its mRNA-based COVID-19 vaccine because it believes it will be too late in reaching the market, STAT news reported. Sanofi... 
Via Benzinga
Exposures COVID-19
The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer's Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27) Acceleron Pharma Inc. (... 
Via Benzinga
Analyst Upgrades Sanofi On COVID-19 Vaccine Optimism
Sanofi SA (NASDAQ:SNY) shares traded higher by 0.4% on Mond... 
Via Benzinga
Exposures COVID-19
Acceleron In Advanced $11B Buyout Talks: Bloomberg
Frothy rumors about possible M&A discussions at Acceleron Pharma Inc (NASDAQ: XLRN) were capped with a Bloomberg report asserting that the Company is... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2021
Upgrades According to Roth Capital, the prior rating for Seelos Therapeutics Inc (NASDAQ: 
Via Benzinga
Pfizer Nabs Booster OK In U.S. — But How Long Will It Hold The Covid Lead?
The FDA allowed the Pfizer-BioNTech Covid booster for some. But rivals are coming. 
Via Investor's Business Daily
Exposures Product Safety
Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen. ... 
Via Benzinga
AbbVie's Pain Is Sanofi's and Regeneron's Gain
There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors. 
Via The Motley Fool
Exposures Product Safety
The Week Ahead In Biotech (Sept. 12-18): Calliditas FDA Decision, Adcom Review For Pfizer/BioNTech COVID-19 Vaccine, Oncology Conference And IPOs
Biotech stocks retreated in the holiday-shortened week ending Sept. 10, reversing course from the previous week. Humanigen, Inc. (NASDAQ: HGEN) was among the biggest... 
Via Benzinga
Exposures COVID-19 Product Safety
Week In Review: Sanofi Acquires Kadmon, A US-China Pharma, For $1.9 Billion
France's Sanofi will acquire Kadmon Holdings​​ of New York City in a $1.9 billion deal. In 2019, Kadmon formed a JV with BioNova Pharma to develop its novel lead drug, Rezurock (belumosudil) in China. 
Via Talk Markets
Can Pfizer Beat Sanofi and Regeneron in the Eczema Market?
Pfizer's abrocitinib faces some challenges despite encouraging late-stage results for the drug in treating eczema. 
Via The Motley Fool
EMA Gives Nod To Additional Sites For Pfizer - BioNTech COVID-19 Vaccine
European Medical Agency (EMA) has approved additional manufacturing sites to produce Comirnaty, the COVID-19 vaccine developed by Pfizer Inc (NYSE: PFE) and... 
Via Benzinga
Exposures COVID-19
Sanofi's BTK Inhibitor Disappoints In Phase 3 Autoimmune Disease Trial
Sanofi SA's (NASDAQ: SNY) BTK inhibitor, rilzabrutinib, has flunked its first major clinical test. Rilzabrutinib was Principia Biopharma Inc's one of the... 
Via Benzinga
The Daily Biotech Pulse: ProQR-Lilly R&D Partnership, Sanofi's Pemphigus Trial Disappointment, Humanigen's COVID-19 Drug Denied Emergency Use Authorization
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 8) Abbott Laboratories (NYSE:... 
Via Benzinga
Exposures COVID-19
KDMN Stock: 6 Things to Know About Biopharma Kadmon Holdings as Shares Skyrocket
Kadmon Holdings (KDMN) stock is rising higher on Wednesday following news of a deal with Sanofi (SNY) that comes to $1.9 billion. 
Via InvestorPlace
Kadmon Stock Hits 5-Year High On Sanofi's $1.9 Billion Takeover
Sanofi said Wednesday it will spend $1.9 billion to acquire small biotech Kadmon Holdings, and KDMN stock rocketed to a five-year high. 
Via Investor's Business Daily
Why Kadmon Holdings Stock Is Rocketing Higher Today
Sanofi adds another bolt-on acquisition in what is turning out to be a busy year for the French pharma titan. 
Via The Motley Fool
Sanofi's $1.9 Billion Bet On Kadmon: What You Need to Know
Underlining the focus on inorganic growth, French pharma giant Sanofi (NASDAQ: SNY) announced a big-ticket acquisition just a month after another billion-dollar... 
Via Benzinga
Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates
August proved to be a mixed month for regulatory approvals, with the Food and Drug Administration approving a few, turning down a few others and delaying the remaining. New... 
Via Benzinga
Glaxo, SK Bioscience Start COVID-19 Vaccine Trial Against AstraZeneca Shot
GlaxoSmithKline Plc (NYSE: GSK) has started Phase 3 clinical study for a COVID-19 vaccine candidate designed by South Korean drugmaker SK Bioscience Co. The... 
Via Benzinga
Exposures COVID-19
Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial
Pfizer Inc (NYSE: PFE) announced topline data from the JADE DARE Phase 3 trial comparing abrocitinib with Sanofi SA (NASDAQ: SNY) - Regeneron... 
Via Benzinga
Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis
A Phase 3 trial evaluating Dupixent (dupilumab) for treating children aged 6 months to 5 years with moderate-to-severe atopic dermatitis met its primary and secondary... 
Via Benzinga
Surprise! Here's the Cheapest COVID Vaccine Stock on the Market Right Now
The least expensive COVID-19 vaccine stock right now isn't one of the leaders in the market -- at least not yet. 
Via The Motley Fool
Exposures COVID-19
Roche's Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage
Roche Holdings AG's (OTCQX: RHHBF) drug Actemra, or tocilizumab, was granted FDA emergency use authorization for critically ill COVID-19 patients after... 
Via Benzinga
Exposures COVID-19 Product Safety
Inside Sanofi's $3.2B Translate Bio Buyout
Before the $3.2 billion acquisition of mRNA player Translate Bio Inc (NASDAQ: TBIO) earlier this month, Sanofi SA (NASDAQ: SNY) expressed interest... 
Via Benzinga
Unusual Options Activity Insight: Sanofi
Sanofi (NASDAQ:SNY) shares experienced unusual options activity on Monday. The stock price moved up to $51.84 following the option alert. Sentiment: BULLISH Option Type: SWEEP... 
Via Benzinga
< Previous 1 2
...
19 20 21 22 23 24 25 26 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.